Compare ESPR & TRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESPR | TRTX |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 660.1M | 708.3M |
| IPO Year | 2013 | 2017 |
| Metric | ESPR | TRTX |
|---|---|---|
| Price | $3.70 | $8.98 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 3 |
| Target Price | $6.86 | ★ $10.75 |
| AVG Volume (30 Days) | ★ 7.0M | 521.7K |
| Earning Date | 11-06-2025 | 10-28-2025 |
| Dividend Yield | N/A | ★ 10.69% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.65 |
| Revenue | ★ $303,802,000.00 | $138,590,000.00 |
| Revenue This Year | $25.45 | N/A |
| Revenue Next Year | N/A | $8.19 |
| P/E Ratio | ★ N/A | $13.86 |
| Revenue Growth | 2.83 | ★ 4.13 |
| 52 Week Low | $0.69 | $6.47 |
| 52 Week High | $4.03 | $9.85 |
| Indicator | ESPR | TRTX |
|---|---|---|
| Relative Strength Index (RSI) | 63.61 | 51.43 |
| Support Level | $3.59 | $9.02 |
| Resistance Level | $3.91 | $9.18 |
| Average True Range (ATR) | 0.24 | 0.15 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 77.74 | 59.00 |
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
TPG RE Finance Trust Inc is a commercial real estate finance company. It originates, acquires, and manages commercial mortgage loans and other commercial real estate-related debt instruments consisting of first mortgage loans and senior participation interests in first mortgage loans secured by institutional-quality properties in primary and select secondary markets in the United States. The company's objective is to provide attractive risk-adjusted returns to its stockholders over time through cash distributions and capital appreciation. It focuses on directly originating and selectively acquiring floating rate first mortgage loans that are secured by high quality commercial real estate properties undergoing some form of transition and value creation.